Grifols S.A. SWOT and PESTLE Analysis
COMPANY PROFILE -Grifols S.A.
Business Sector :Healthcare
Operating Geography :Spain, Europe, Global
About Grifols S.A. :
Having its headquarters in Spain, Grifols SA is a multinational specialised pharmaceutical firm that creates, produces, and distributes a wide variety of biological drugs based on proteins extracted from plasma. The laboratory that hematologist and scientist Dr Josep A. Grifols Roig established in Barcelona in 1940 is where Grifols got its start. It divides its operations into the following five categories: bioscience, diagnostic, hospitals, bio supplies, and others. The production of plasma derivatives for therapeutic purposes as well as the marketing and distribution of finished goods are all included in the field of biology. Diagnostics is primarily concerned with the development, manufacture, and marketing of in-vitro diagnostics products for laboratories, including analytical tools, reagents, and software. The hospital supplies physiological saline solution, enteral nutritional fluids, medical devices for interventional therapy, as well as technologies and services for hospitals, clinics, and specialized facilities for the creation of medications. Most of the items offered by Bio Supplies are biological for non-therapeutic use. Others offer manufacturing services to independent businesses. The corporation announced in April 2022 that it had completed the acquisition of Biotest, a strategic and transformative move meant to spur development and innovation.
The unique selling proposition of Grifols is that it has been a pioneer in plasma-derived medicines for more than 110 years, enhancing people's health and well-being. The mission statement of Grifols reads, "Every day all Grifols employees work toward our mission of improving the health and well-being of people around the world. Our plasma-derived medicines and other innovative solutions treat millions of patients with chronic, rare and prevalent, sometimes, life-threatening diseases".
Grifols S.A. Revenue :
€ 4,933 million - FY ending 31st December 2021
€ 5,353 million - FY ending 31st December 2020
Competitive Analysis of Grifols S.A.
Strengths | Weaknesses |
1. Outstanding manufacturing ability diversified across geography 2. Vertically integrated business model improving overall efficiency 3. World class R&D capabilities 4. Inhouse engineering to lead Grifols manufacturing projects | 1. High dependence on bioscience division for its revenue 2. Poor shareholders return compared to biotech industry and Spanish share market 3. High debt eroding company profitability 4. Downgrading of company ratings by S&P global and Moody’s |
Opportunities | Threats |
1. Strategic partnership to drive growth in China 2. Expand plasma center network to increase access to plasma 3. Increased demand for plasma therapy due to Covid-19 | 1. Misconceptions related to plasma therapy 2. Decrease in plasma donations threatens company output 3. Rising covid-19 cases can affect Grifols operations |
Complete Report
USD 27
- Debit/Credit card
- PayPal
Detailed SWOT Analysis of Grifols S.A.
Strength
1. Outstanding production capability diversified across geography: Grifols has diversified its production capability across different geography worldwide with its main focus on four divisions Bioscience, Hospital, Diagnostic and Bio supplies. The company has 264 plasma centers in the US, 48 in Europe and 22 in China through Shanghai RAAS. It has 16 industrial facilities, 10 R&D centers, 6 Bioscience division centers, 8 Hospital division centers, 3 Diagnostic division centers and 2 Bio supplies division centers spread across the world. Grifols plasma derived can be manufactured interchangeably at its plant in the US and Spain, this will help in maximizing efficiency and optimizing profitability while also ensuring higher standard of quality and safety.
The remaining section under "Strength" is available only in the 'Complete Report' on purchase.
Weakness
This section is available only in the 'Complete Report' on purchase.
Opportunity
This section is available only in the 'Complete Report' on purchase.
Threat
This section is available only in the 'Complete Report' on purchase.
Major Competitors :
- CSL
- Shire
- Octapharma
- Kedrion
- BPL
- Sanquin
- LFB
- Japan Blood Products Organization
Major Brands :
- SeraCare
- Biomat
- Grifols Engineering
Complete Report
USD 27
- Debit/Credit card
- PayPal
TABLE OF CONTENTS
DELIVERY AND FORMAT
WHY CHOOSE US?
You may also be interested in other analyses of Grifols S.A.:
-
Grifols S.A. Porter's Five Forces Analysis -
Grifols S.A. VRIO Analysis -
Grifols S.A. Value Chain Analysis -
Grifols S.A. Covid-19 Impact Analysis -
Grifols S.A. BCG Analysis -
Grifols S.A. Segmentation, Targeting and Positioning (STP) Analysis -
Grifols S.A. Ansoff Matrix Analysis
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Check Out Analysis of Other Relevant Companies
References used in Grifols S.A. SWOT & PESTLE Analysis Report
1. Annual Report - https://www.grifols.com/documents/51507592/1025432068/Grifols+Integrated+Annual+Report_2020.pdf/116dc859-8b53-4045-bb29-35a8a8b6a7e8
2. Debt to Equity History and Analysis - https://simplywall.st/stocks/es/pharmaceuticals-biotech/bme-grf/grifols-shares#historical-debt
3. Recommendations for Investigational COVID-19 Convalescent Plasma - https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-applications-inds-cber-regulated-products/recommendations-investigational-covid-19-convalescent-plasma
4. Rising Inflation Widespread Globally, but US Stands Out - https://www.fitchratings.com/research/sovereigns/rising-inflation-widespread-globally-us-stands-out-14-12-2021
The detailed complete set of references are available on request in the 'Complete report' on purchase.
How to Reference This Page?
You can use the following in your reference section in order to give credit to the source. For different referencing styles and detailed guidelines, please click here.
Grifols S.A. SWOT and PESTLE Analysis - SWOT & PESTLE.COM
SWOT & PESTLE.com (2025). Grifols S.A. SWOT and PESTLE Analysis - SWOT & PESTLE.com. [online] Available at: https://www.swotandpestle.com/grifols/ [Accessed 23 Jan, 2025].
In-text: (SWOT & PESTLE.com, 2025)
Copyrights and Disclaimer
Grifols S.A. SWOT and PESTLE analysis has been conducted by Pratik Vora and reviewed by senior analysts from Barakaat Consulting.
Copyright of Grifols S.A. SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.